In Re: Fosamax

VERDICT

Trial
01/24/11 – 02/14/11

Summary

Rosenberg v. Merck will be the fourth FOSAMAX trial, and the first in state court. The prior three trials, in federal court, resulted in two defense verdicts and a plaintiff verdict.

In this product liability litigation proceeding, plaintiff Alison Rosenberg alleged Merck & Company Inc. of fraudulent concealment of the risk associated with its drug ‘FOSAMAX’ due to which she suffered jaw related problems. Merck claimed that Ms. Rosenberg's jaw-related problems resulted from other health problems and medications.

Alendronate Sodium, sold by Merck under the brand name "FOSAMAX" since 1995, is an osteoporosis treatment for postmenopausal women. Some studies have shown that oral bisphosphonates, including Fosamax, may increase the result of osteonecrosis of the jaw (ONJ), or bone death.

The plaintiff was represented by attorney J. Paul Sizemore. The defendant in this case, Merck and Co was represented by attorney Christy Jones.

The jury concluded that Ms. Rosenberg did not suffer from osteonecrosis of the jaw (ONJ), and therefore she failed to show that Fosamax caused the harm.

For more information, visit the CVN News Blog.

Outcome

Jury found for the Defense.

Sessions

PM Session
Plaintiff Witness(es)
2 Chapters
JAN
26
PM Session
Defense Witness(es)
2 Chapters
FEB
2
AM Session
Closings
2 Chapters
PM Session
Closings
2 Chapters
FEB
9
AM Session
Other
2 Chapters
FEB
10
AM Session
Verdict
2 Chapters
FEB
14

Recording Disclaimer: This proceeding was recorded in full.

Suggest a Trial

Want to see a trial that you don't see in our list of upcoming trials?

Suggest a Case

CVN Essentials

The most important and informative moments of each trial

CVN Essentials

Video Library

Unlimited access to thousands of hours of past coverage of high stakes civil litigation

Video Library

  • Follow Us
  • Contact Us
  • 4901 Olde Towne Parkway
  • Suite 100
  • Marietta, GA 30068
  • 877-834-8627
  • 404-935-0321

Copyright 2024 Courtroom Connect.